Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of MRSA infection: a health-care system perspective

von Dach, E., Morel, C. M., Murthy, A., Pagani, L., Macedo-Vinas, M., Olearo, F. & Harbarth, S. (2017). Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of MRSA infection: a health-care system perspective. Clinical Microbiology and Infection, 23(9), 659-666. https://doi.org/10.1016/j.cmi.2017.02.011
Copy

To date few industry-independent studies were conducted to compare the relative costs and benefits of drugs to treat MRSA infection. We performed a stochastic cost-effectiveness analysis comparing two treatment strategies -- linezolid versus trimethoprim-sulfamethoxazole plus rifampicin -- for the treatment of MRSA infection.
Item Type Article
Copyright holders © 2017 The Authors © CC BY-NC-ND 4.0
Departments LSE > Academic Departments > Social Policy
LSE > Research Centres > LSE Health
DOI 10.1016/j.cmi.2017.02.011
Date Deposited 01 Mar 2017
Acceptance Date 10 Feb 2017
URI https://researchonline.lse.ac.uk/id/eprint/69613

Explore Further

picture_as_pdf
subject
Accepted Version
Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
Download

Export as

EndNote BibTeX Reference Manager Refer Atom Dublin Core JSON Multiline CSV
Export

Downloads
View more statistics